Article and Video CATEGORIES
This is part 2 of my round table case discussion with Dr. Anne Tsao, a medical oncologist and thoracic oncology expert from MD Anderson Cancer Center in Houston, and Dr. Alex Farivar, a thoracic surgeon with expert training in mesothelioma at Swedish Cancer Institute in Seattle. This particular case covers a patient with a mesothelioma, cancer of the lining around the lung, which is also known as malignant pleural mesothelioma.
Here is the audio and video versions of the podcast, along with the transcript and figures.
[powerpress]
round-table-with-drs-tsao-and-farivar-part-2-meso-case-audio-podcast
round-table-with-drs-tsao-and-farivar-part-2-meso-case-transcript
round-table-with-drs-tsao-and-farivar-part-2-meso-case-figures
By the way, my apologies for the poor audio quality, a combination of inadequate recording, passing buses outside of the public space we were in, etc. It's audible and still useful to people who are interested in learning about this topic, but this recording is below the standard for which we're striving. To be honest, part of the audio quality issue was that we went for a lower cost sound guy, and it shows. So please consider a contribution, because it goes for things like having our podcasts sound better. You get what you pay for, and we would prefer to do better than "shoestring budget" quality.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…